About Cancer Genetics (NASDAQ:CGIX)
Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Healthcare Facilities & Services
- Sub-Industry: N/A
- Symbol: NASDAQ:CGIX
- CUSIP: N/A
- Web: www.cancergenetics.com
Capitalization:- Market Cap: $53.43 million
- Outstanding Shares: 19,790,000
Average Prices:- 50 Day Moving Avg: $2.95
- 200 Day Moving Avg: $3.60
- 52 Week Range: $1.10 - $5.30
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -15.88
- P/E Growth: -0.08
Sales & Book Value:- Annual Revenue: $27.55 million
- Price / Sales: 1.94
- Book Value: $0.94 per share
- Price / Book: 2.87
Profitability:- EBITDA: ($11,120,000.00)
- Net Margins: -68.48%
- Return on Equity: -48.78%
- Return on Assets: -26.29%
Debt:- Debt-to-Equity Ratio: 0.30%
- Current Ratio: 2.40%
- Quick Ratio: 2.40%
Misc:- Average Volume: 103,729 shs.
- Beta: 1.19
- Short Ratio: 18.42
Frequently Asked Questions for Cancer Genetics (NASDAQ:CGIX)
What is Cancer Genetics' stock symbol?
Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."
How were Cancer Genetics' earnings last quarter?
Cancer Genetics, Inc. (NASDAQ:CGIX) announced its quarterly earnings results on Monday, August, 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.16). The business had revenue of $6.60 million for the quarter, compared to the consensus estimate of $7.97 million. Cancer Genetics had a negative return on equity of 48.78% and a negative net margin of 68.48%. The business's revenue was down 5.7% compared to the same quarter last year. During the same period last year, the business posted ($0.28) EPS. View Cancer Genetics' Earnings History.
Where is Cancer Genetics' stock going? Where will Cancer Genetics' stock price be in 2017?
3 brokerages have issued 1-year price targets for Cancer Genetics' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Cancer Genetics' share price to reach $6.00 in the next year. View Analyst Ratings for Cancer Genetics.
Who are some of Cancer Genetics' key competitors?
Some companies that are related to Cancer Genetics include Otonomy (OTIC), ProQR Therapeutics N.V. (PRQR), CTI BioPharma Corp. (CTIC), Protalix Biotherapeutics (PLX), Medicure (MCUJF), Eiger BioPharmaceuticals (EIGR), Zafgen (ZFGN), CytoDyn (CYDY), Gemphire Therapeutics (GEMP), Viveve Medical (VIVE), Aralez Pharmaceuticals (ARLZ), Trevena (TRVN), Versartis (VSAR), MEI Pharma (MEIP), Genesis Healthcare (GEN), Alimera Sciences (ALIM), Galmed Pharmaceuticals (GLMD) and EDAP TMS S.A. (EDAP).
Who are Cancer Genetics' key executives?
Cancer Genetics' management team includes the folowing people:
- John G. Pappajohn, Chairman of the Board
- Panna L. Sharma, President, Chief Executive Officer, Director, IR Contact Officer
- John A. Roberts, Chief Financial Officer, Principal Financial Officer
- Igor Gitelman CPA, Chief Accounting Officer, Principal Accounting Officer
- Rita Shaknovich, Medical Director, Vice President - Hematopathology Services
- Jane Houldsworth Ph.D., Vice President - Research & Development
- Raju S. K. Chaganti Ph.D., Director
- Geoffrey Eric Harris, Director
- Edmund M. Cannon, Independent Director
- Howard McLeod Pharm. D., Independent Director
How do I buy Cancer Genetics stock?
Shares of Cancer Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cancer Genetics' stock price today?
One share of Cancer Genetics stock can currently be purchased for approximately $2.70.
MarketBeat Community Rating for Cancer Genetics (NASDAQ CGIX)MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cancer Genetics (NASDAQ:CGIX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $6.00 (122.22% upside) |
Consensus Price Target History for Cancer Genetics (NASDAQ:CGIX)
Analysts' Ratings History for Cancer Genetics (NASDAQ:CGIX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/21/2017 | HC Wainwright | Reiterated Rating | Buy | $6.00 | Medium |  |
| 6/27/2017 | Dawson James | Initiated Coverage | Buy | | High | |
| 6/26/2017 | Benchmark Co. | Initiated Coverage | Speculative Buy | $3.85 -> $6.00 | High | |
| 9/26/2016 | Rodman & Renshaw | Initiated Coverage | Buy | $6.00 | N/A | |
| 3/15/2016 | Aegis | Boost Price Target | Buy | $8.00 -> $15.00 | N/A | |
| 3/11/2016 | Janney Montgomery Scott | Reiterated Rating | Buy -> Neutral | | N/A | |
(Data available from 10/19/2015 forward)
Earnings History for Cancer Genetics (NASDAQ:CGIX)Earnings History by Quarter for Cancer Genetics (NASDAQ CGIX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/14/2017 | Q2 2017 | ($0.16) | ($0.16) | $7.97 million | $6.60 million | View | N/A | |
| 5/11/2017 | Q1 2017 | ($0.18) | ($0.11) | $7.62 million | $7.00 million | View | N/A | |
| 3/23/2017 | Q4 2016 | ($0.22) | ($0.15) | $7.10 million | $7.23 million | View | N/A | |
| 11/10/2016 | Q316 | ($0.28) | ($0.23) | $6.93 million | $6.80 million | View | N/A | |
| 8/9/2016 | Q216 | ($0.33) | ($0.28) | $6.50 million | $7.00 million | View | N/A | |
| 5/10/2016 | Q1 | ($0.43) | ($0.39) | $6.95 million | $6.10 million | View | Listen | |
| 3/10/2016 | Q415 | ($0.46) | ($0.48) | $7.00 million | $5.50 million | View | Listen | |
| 11/10/2015 | Q315 | ($0.49) | ($0.56) | $5.13 million | $4.00 million | View | Listen | |
| 8/11/2015 | Q215 | ($0.50) | ($0.51) | $4.67 million | $4.20 million | View | Listen | |
| 5/12/2015 | Q115 | ($0.54) | ($0.43) | $3.91 million | $4.40 million | View | Listen | |
| 3/12/2015 | Q414 | ($0.52) | ($0.49) | $3.70 million | $4.00 million | View | N/A | |
| 11/10/2014 | Q3 2014 | ($0.51) | ($0.41) | $3.11 million | $3.22 million | View | N/A | |
| 8/14/2014 | Q214 | ($0.39) | ($0.50) | $2.13 million | $3.20 million | View | N/A | |
| 5/15/2014 | Q114 | ($0.29) | ($0.27) | $2.17 million | $1.40 million | View | N/A | |
| 3/26/2014 | Q4 13 | ($0.36) | ($0.37) | $1.95 million | $1.90 million | View | N/A | |
| 11/13/2013 | Q313 | ($0.71) | ($0.61) | $1.60 million | $1.70 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cancer Genetics (NASDAQ:CGIX)2017 EPS Consensus Estimate: ($0.52)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.18) | ($0.18) | ($0.18) |
| Q2 2017 | 2 | ($0.15) | ($0.14) | ($0.15) |
| Q3 2017 | 2 | ($0.12) | ($0.12) | ($0.12) |
| Q4 2017 | 2 | ($0.09) | ($0.05) | ($0.07) |
(Data provided by Zacks Investment Research)
Dividend History for Cancer Genetics (NASDAQ:CGIX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cancer Genetics (NASDAQ:CGIX)Insider Ownership Percentage: 21.30%
Institutional Ownership Percentage: 16.08%
Insider Trades by Quarter for Cancer Genetics (NASDAQ:CGIX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/18/2017 | John Pappajohn | Director | Buy | 86,185 | $3.24 | $279,239.40 | |
| 8/17/2017 | John Pappajohn | Director | Buy | 86,185 | $3.24 | $279,239.40 | |
| 6/12/2017 | John Pappajohn | Director | Buy | 100,000 | $3.75 | $375,000.00 | |
| 5/25/2017 | Igor Gitelman | Insider | Buy | 937 | $3.95 | $3,701.15 | |
| 5/23/2017 | Igor Gitelman | Insider | Sell | 937 | $4.02 | $3,766.74 | |
| 5/16/2017 | Geoffrey E Harris | Director | Buy | 2,500 | $3.75 | $9,375.00 | |
| 12/14/2016 | Geoffrey E Harris | Director | Buy | 2,500 | $1.50 | $3,750.00 | |
| 11/28/2016 | John Pappajohn | Director | Buy | 100,000 | $1.45 | $145,000.00 | |
| 11/16/2016 | Edward J Sitar | CFO | Sell | 3,333 | $1.56 | $5,199.48 | |
| 11/14/2016 | John Pappajohn | Director | Buy | 31,100 | $1.48 | $46,028.00 | |
| 8/16/2016 | John Pappajohn | Director | Buy | 45,000 | $2.29 | $103,050.00 | |
| 8/15/2016 | John Pappajohn | Director | Buy | 147,500 | $2.16 | $318,600.00 | |
| 3/17/2016 | John Pappajohn | Director | Buy | 50,000 | $2.64 | $132,000.00 | |
| 3/17/2016 | Panna Sharma | CEO | Buy | 1,500 | $2.59 | $3,885.00 | |
| 3/16/2016 | John Pappajohn | Director | Buy | 100,000 | $2.53 | $253,000.00 | |
| 3/15/2016 | Panna Sharma | CEO | Buy | 1,000 | $2.56 | $2,560.00 | |
| 8/27/2015 | John Pappajohn | Director | Buy | 5,000 | $9.61 | $48,050.00 | |
| 6/25/2015 | Raju S.K. Chaganti | Director | Sell | 5,296 | $12.00 | $63,552.00 | |
| 6/12/2015 | Raju S.K. Chaganti | Director | Sell | 7,000 | $12.01 | $84,070.00 | |
| 6/11/2015 | Raju S.K. Chaganti | Director | Sell | 46,454 | $12.03 | $558,841.62 | |
| 6/8/2015 | Raju S.K. Chaganti | Director | Sell | 24,583 | $12.03 | $295,733.49 | |
| 5/14/2015 | John Pappajohn | Director | Buy | 5,000 | $10.74 | $53,700.00 | |
| 3/17/2015 | John Pappajohn | Director | Buy | 50,000 | $7.36 | $368,000.00 | |
| 3/16/2015 | Edward J Sitar | CFO | Buy | 1,000 | $6.99 | $6,990.00 | |
| 12/16/2014 | John Pappajohn | Director | Buy | 5,589 | $6.20 | $34,651.80 | |
| 12/15/2014 | John Pappajohn | Director | Buy | 3,634 | $6.14 | $22,312.76 | |
| 12/11/2014 | John Pappajohn | Director | Buy | 27,087 | $6.03 | $163,334.61 | |
| 12/10/2014 | John Pappajohn | Director | Buy | 5,773 | $5.96 | $34,407.08 | |
| 12/9/2014 | John Pappajohn | Director | Buy | 39,686 | $5.35 | $212,320.10 | |
| 5/21/2014 | Edward Sitar | CFO | Buy | 1,000 | $10.67 | $10,670.00 | |
| 5/21/2014 | John Pappajohn | Director | Buy | 50,000 | $10.31 | $515,500.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cancer Genetics (NASDAQ:CGIX)
Latest Headlines for Cancer Genetics (NASDAQ:CGIX)
| Source: |
|
| Date | Headline |
|---|
 | Cancer Genetics, Inc. to Host Panel Discussion on “The Convergence of Artificial Intelligence and Healthcare - New ... - Nasdaq
www.nasdaq.com - October 13 at 4:01 AM |
 | Cancer Genetics, Inc. to Host Panel Discussion on “The Convergence of Artificial Intelligence and Healthcare - New Developments in Precision Medicine” During the 3rd Annual Dawson James Small Cap Growth Conference on October 18th
finance.yahoo.com - October 12 at 5:56 PM |
 | Cancer Genetics, Inc. to Host Panel Discussion on "The Convergence of Artificial Intelligence and Healthcare - New Developments in Precision Medicine" During the 3rd Annual Dawson James Small Cap Growth Conference on October 18th
feeds.benzinga.com - October 12 at 7:49 AM |
 | Cancer Genetics (CGIX) vs. Chemed Corp. (CHE) Head-To-Head Review
www.americanbankingnews.com - October 11 at 12:24 PM |
| ETFs with exposure to Cancer Genetics, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 5:47 PM |
| Head-To-Head Analysis: Tenet Healthcare Corporation (THC) vs. Cancer Genetics (CGIX)
www.americanbankingnews.com - October 4 at 2:10 AM |
| Analysts Expect Cancer Genetics, Inc. (CGIX) Will Post Quarterly Sales of $8.36 Million
www.americanbankingnews.com - October 1 at 5:06 AM |
| Cancer Genetics, Inc. to Present at The MicroCap Conference on October 5th in New York City at the Essex House
feeds.benzinga.com - September 29 at 8:21 AM |
 | Cancer Genetics, Inc. to Present at The MicroCap Conference on October 5th in New York City at the Essex House - GlobeNewswire (press release)
globenewswire.com - September 29 at 8:19 AM |
| ETFs with exposure to Cancer Genetics, Inc. : September 26, 2017
finance.yahoo.com - September 26 at 4:05 PM |
| Cancer Genetics, Inc. :CGIX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017
finance.yahoo.com - September 25 at 7:39 PM |
| Cancer Genetics, Inc. to Present at the 2017 Disruptive Growth Company Showcase NYC on September 27th - GlobeNewswire (press release)
globenewswire.com - September 23 at 10:02 PM |
| Cancer Genetics, Inc. to Present at the 2017 Disruptive Growth Company Showcase NYC on September 27th - Nasdaq
www.nasdaq.com - September 22 at 10:08 AM |
| Cancer Genetics, Inc. to Present at the 2017 Disruptive Growth Company Showcase NYC on September 27th
finance.yahoo.com - September 22 at 10:08 AM |
| Financial Analysis: Cancer Genetics (CGIX) versus Its Rivals
www.americanbankingnews.com - September 22 at 2:20 AM |
| HC Wainwright Reaffirms "Buy" Rating for Cancer Genetics, Inc. (CGIX)
www.americanbankingnews.com - September 21 at 8:56 PM |
| Cancer Genetics, Inc. Announces 25th Contract Win to Provide Testing & Diagnostic Services for Combination Immuno-Oncology Clinical Trial
finance.yahoo.com - September 20 at 5:53 PM |
| Cancer Genetics, Inc. (CGIX) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - September 10 at 6:24 PM |
| Cancer Genetics, Inc. Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference ... - GlobeNewswire (press release)
globenewswire.com - September 9 at 3:36 AM |
| Cancer Genetics, Inc. Announces Participation at the 19th Annual Rodman & Renshaw Global Investment
www.nasdaq.com - September 8 at 5:29 PM |
| Cancer Genetics, Inc. Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City, September 10-12, 2017
finance.yahoo.com - September 8 at 5:29 PM |
| Cancer Genetics, Inc. (CGIX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 1 at 10:32 PM |
| Analyzing Cancer Genetics (CGIX) and China Cord Blood Corporation (CO)
www.americanbankingnews.com - September 1 at 12:20 PM |
| Earnings Review and Free Research Report: Quintiles IMS Reported Better than Expected Revenue and Earnings Results
finance.yahoo.com - August 22 at 10:43 PM |
| Insider Buying: Cancer Genetics, Inc. (CGIX) Director Purchases 86,185 Shares of Stock
www.americanbankingnews.com - August 18 at 8:08 PM |
| Insider Buying: Cancer Genetics, Inc. (CGIX) Director Acquires 86,185 Shares of Stock
www.americanbankingnews.com - August 18 at 8:08 PM |
| Cancer Genetics, Inc. to Host Conference Call to Discuss Strategic and Business Rationale of vivoPharm Acquisition
finance.yahoo.com - August 16 at 5:35 PM |
| Today's Research Reports on Stocks to Watch: Cancer Genetics and MiMedx Group
finance.yahoo.com - August 16 at 5:35 PM |
| Cancer Genetics, Inc. to Host Conference Call to Discuss Strategic and Business Rationale of vivoPharm Acquisition
feeds.benzinga.com - August 16 at 7:43 AM |
| Cancer Genetics Inc (CGIX) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 15 at 6:40 PM |
| Edited Transcript of CGIX earnings conference call or presentation 14-Aug-17 9:00pm GMT
finance.yahoo.com - August 15 at 5:51 PM |
| Cancer Genetics, Inc. (CGIX) Posts Earnings Results
www.americanbankingnews.com - August 15 at 9:41 AM |
 | BRIEF-Cancer Genetics reports Q2 loss per share $0.16
www.reuters.com - August 14 at 10:35 PM |
| Earnings Reaction History: Cancer Genetics, Inc., 66.7% Follow-Through Indicator, 7.7% Sensitive - Nasdaq
www.nasdaq.com - August 14 at 5:33 PM |
| Cancer Genetics, Inc. Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise
finance.yahoo.com - August 14 at 5:33 PM |
| Cancer Genetics Announces Transformative and Accretive Acquisition of vivoPharm, a Global Oncology & Immuno-Oncology Discovery Services Company
finance.yahoo.com - August 14 at 5:33 PM |
| Cancer Genetics reports 2Q loss
finance.yahoo.com - August 14 at 5:33 PM |
| Cancer Genetics to Hold Second Quarter 2017 Earnings Call on Monday, August 14th - GlobeNewswire (press release)
globenewswire.com - August 9 at 2:57 AM |
| Cancer Genetics to Hold Second Quarter 2017 Earnings Call on Monday, August 14th
finance.yahoo.com - August 7 at 5:35 PM |
| Brokerages Expect Cancer Genetics, Inc. (NASDAQ:CGIX) Will Announce Quarterly Sales of $8.35 Million
www.americanbankingnews.com - August 6 at 7:00 AM |
| Contrasting Cancer Genetics (CGIX) and HealthStream (HSTM)
www.americanbankingnews.com - August 4 at 12:28 PM |
| DIA Elects Cancer Genetics, Inc.'s John A. (Jay) Roberts as Chairman of DIA Board of Directors - Nasdaq
www.nasdaq.com - August 3 at 6:43 PM |
| DIA Elects Cancer Genetics, Inc.'s John A. (Jay) Roberts as ... - GlobeNewswire (press release)
globenewswire.com - August 3 at 6:43 PM |
| DIA Elects Cancer Genetics, Inc.’s John A. (Jay) Roberts as Chairman of DIA Board of Directors
finance.yahoo.com - August 3 at 6:43 PM |
| ETFs with exposure to Cancer Genetics, Inc. : August 1, 2017
finance.yahoo.com - August 1 at 5:49 PM |
| Cancer Genetics, Inc. Acclaimed by Frost & Sullivan For North American Technology Innovation in Precision Oncology - Nasdaq
www.nasdaq.com - July 27 at 9:36 PM |
| Cancer Genetics, Inc. Acclaimed by Frost & Sullivan For North American Technology Innovation in Precision Oncology
finance.yahoo.com - July 27 at 4:35 PM |
| Cancer Genetics, Inc. (CGIX) Expected to Post Quarterly Sales of $8.35 Million
www.americanbankingnews.com - July 15 at 7:50 AM |
| Cancer Genetics, Inc. (NASDAQ:CGIX) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - July 13 at 6:18 PM |
| ETFs with exposure to Cancer Genetics, Inc. : July 6, 2017
finance.yahoo.com - July 6 at 6:22 PM |
Cancer Genetics (CGIX) Chart for Thursday, October, 19, 2017
